A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

被引：0
|
作者：
Roche Kapoor
Matthew P. Deek
Riley McIntyre
Natasha Raman
Megan Kummerlowe
Iyah Chen
Matt Gaver
Hao Wang
Sam Denmeade
Tamara Lotan
Channing Paller
Mark Markowski
Michael Carducci
Mario Eisenberger
Tomasz M. Beer
Daniel Y. Song
Theodore L. DeWeese
Jason W. Hearn
Stephen Greco
Curtiland DeVille
Neil B. Desai
Elisabeth I. Heath
Stanley Liauw
Daniel E. Spratt
Arthur Y. Hung
Emmanuel S. Antonarakis
Phuoc T. Tran
机构：
[1] Sidney Kimmel Comprehensive Cancer Center,Department of Radiation Oncology and Molecular Radiation Sciences
[2] Johns Hopkins Hospital,Department of Medical Oncology
[3] Sidney Kimmel Comprehensive Cancer Center,The James Buchanan Brady Urological Institute and Department of Urology
[4] Johns Hopkins Hospital,Department of Pathology
[5] Johns Hopkins University School of Medicine,OHSU Knight Cancer Institute
[6] Johns Hopkins University School of Medicine,Department of Radiation Oncology
[7] Oregon Health & Science University,Department of Radiation Oncology
[8] University of Michigan,Karmanos Cancer Institute, Department of Oncology
[9] University of Texas Southwestern Medical Center,Department of Radiation Oncology and Cellular Oncology
[10] Wayne State University School of Medicine,Department of Radiation Medicine
[11] University of Chicago,undefined
[12] OHSU Knight Cancer Institute,undefined
[13] Oregon Health & Science University,undefined
来源：
BMC Cancer | / 19卷
关键词：
Recurrent prostate cancer; Salvage radiation therapy (SRT); High-risk prostate cancer; Enzalutamide; Prostatectomy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
    Taplin, Mary-Ellen
    Gleave, Martin
    Evans, Christopher P.
    Efstathiou, Eleni
    Kantoff, Philip W.
    Ross, Ashley
    Shore, Neal D.
    Briganti, Alberto
    Hadaschik, Boris A.
    Heidenreich, Axel
    Rooney, Oliver Brendan
    Tian, Shaozhou Ken
    Wetherhold, Lisa
    Xu, Weichun
    Cheng, Shinta
    Kibel, Adam S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status
    De Giorgi, U.
    Shore, N.
    Sridharan, S.
    Gleave, M.
    Rosbrook, B.
    Shen, Q.
    Sugg, J.
    Haas, G. P.
    Freedland, S. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S547 - S547
  • [23] CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
    Matsubara, N.
    Agarwal, N.
    Smith, M. R.
    Mckay, R. R.
    Todenhofer, T.
    Piulats Rodriguez, J. M.
    Chung, K. L.
    Heirich, D.
    Sherwood, S.
    Schaverien, C.
    Fasnacht, N.
    Lithio, A.
    Nacerddine, K.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1582 - S1583
  • [24] TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
    Agarwal, N.
    Azad, A. A.
    Mateo, J.
    Shore, N. D.
    Chakrabarti, J.
    Chen, H-C.
    Lanzalone, S.
    Niyazov, A.
    Saad, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S672 - S673
  • [25] Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
    Lorenzo Tosco
    Annouschka Laenen
    Thomas Gevaert
    Isabelle Salmon
    Christine Decaestecker
    Elai Davicioni
    Christine Buerki
    Frank Claessens
    Johan Swinnen
    Karolien Goffin
    Raymond Oyen
    Wouter Everaerts
    Lisa Moris
    Gert De Meerleer
    Karin Haustermans
    Steven Joniau
    BMC Cancer, 18
  • [26] Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
    Tosco, Lorenzo
    Laenen, Annouschka
    Gevaert, Thomas
    Salmon, Isabelle
    Decaestecker, Christine
    Davicioni, Elai
    Buerki, Christine
    Claessens, Frank
    Swinnen, Johan
    Goffin, Karolien
    Oyen, Raymond
    Everaerts, Wouter
    Moris, Lisa
    De Meerleer, Gert
    Haustermans, Karin
    Joniau, Steven
    BMC CANCER, 2018, 18
  • [27] A randomised double-blind placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer
    Horti, J.
    Widmark, A.
    Stenzl, A.
    Turesson, I
    Federico, M. H.
    Abratt, R. P.
    Sanders, N.
    Pover, G. M.
    Bodrogi, L.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 231 - 231
  • [28] Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study
    Yang, T. S.
    Oh, D. Y.
    Guimbaud, R.
    Szanto, J.
    Salek, T.
    Thurzo, L.
    Vieitez, J. M.
    Pover, G. M.
    Kim, T. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
    Agarwal, Neeraj
    Saad, Fred
    Azad, Arun
    Mateo, Joaquin
    Matsubara, Nobuaki
    Shore, Neal D.
    Chakrabarti, Jayeta
    Chen, Hsiang-Chun
    Lanzalone, Silvana
    Niyazov, Alexander
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [30] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).
    Kibel, Adam S.
    Gleave, Martin
    Brookman-May, Sabine D.
    Kim, Won
    Evans, Christopher P.
    Efstathiou, Eleni
    Kantoff, Philip W.
    Ross, Ashley
    Shore, Neal D.
    Briganti, Alberto
    Hadaschik, Boris A.
    Heidenreich, Axel
    Rooney, Oliver Brendan
    Tian, Shaozhou Ken
    Wetherhold, Lisa
    Xu, Weichun
    Parsons, J. Kellogg
    Yeruva, Kesav
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345